医学
前列腺癌
断点群集区域
肿瘤科
DNA甲基化
内科学
癌症
生物标志物
前列腺切除术
计算生物学
基因
生物信息学
生化复发
基因表达
生物
遗传学
受体
作者
Peng Qiao,Di Zhang,Song Zeng,Yicun Wang,Biao Wang,Xiaopeng Hu
出处
期刊:Biomarkers in Medicine
[Future Medicine]
日期:2021-01-01
卷期号:15 (1): 29-41
被引量:5
标识
DOI:10.2217/bmm-2020-0495
摘要
Aim: This study aims to identify novel marker to predict biochemical recurrence (BCR) in prostate cancer patients after radical prostatectomy with negative surgical margin. Materials & methods: The Cancer Genome Atlas database, Gene Expression Omnibus database and Cancer Cell Line Encyclopedia database were employed. The ensemble support vector machine-recursive feature elimination method was performed to select crucial gene for BCR. Results: We identified MYLK as a novel and independent biomarker for BCR in The Cancer Genome Atlas training cohort and confirmed in four independent Gene Expression Omnibus validation cohorts. Multi-omic analysis suggested that MYLK was a DNA methylation-driven gene. Additionally, MYLK had significant positive correlations with immune infiltrations. Conclusion:MYLK was identified and validated as a novel, robust and independent biomarker for BCR in prostate cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI